Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 374.00K | -308.00K | -1.00K | 68.00K | 69.00K |
| Gross Profit | -374.00K | 308.00K | 1.00K | -68.00K | -69.00K |
| SG&A Expenses | 1.50M | 5.15M | 15.38M | 12.64M | -3.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -434.00K | -72.00K | -13.00K | -29.00K | -1.18M |
| Total Operating Expenses | 4.88M | 10.23M | 21.98M | 20.60M | 1.68M |
| Operating Income | -4.88M | -10.23M | -21.98M | -20.60M | -1.68M |
| Income Before Tax | -11.16M | -14.64M | -21.15M | -19.68M | -20.59M |
| Income Tax Expenses | -57.00K | -71.00K | -25.00K | -22.00K | 3.00K |
| Earnings from Continuing Operations | -11.10M | -14.57M | -21.13M | -19.66M | -20.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.00K | 5.00K | 2.00K | 10.00K | 51.00K |
| Net Income | -11.09M | -14.57M | -21.12M | -19.65M | -20.54M |
| EBIT | -4.88M | -10.23M | -21.98M | -20.60M | -1.68M |
| EBITDA | -4.57M | -10.13M | -20.78M | -19.36M | -1.05M |
| EPS Basic | -0.27 | -0.36 | -0.52 | -0.49 | -0.51 |
| Normalized Basic EPS | -0.07 | -0.15 | -0.33 | -0.31 | -0.01 |
| EPS Diluted | -0.27 | -0.36 | -0.52 | -0.49 | -0.51 |
| Normalized Diluted EPS | -0.07 | -0.15 | -0.33 | -0.31 | -0.01 |
| Average Basic Shares Outstanding | 40.83M | 40.66M | 40.34M | 40.27M | 40.16M |
| Average Diluted Shares Outstanding | 40.83M | 40.66M | 40.34M | 40.27M | 40.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |